Cardio- and cerebrovascular risk with conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS) in rheumatic arthritis (RA): a real-world comparative assesment by Prats-Uribe, A, Illingens, B, Vizcaya, D, Weaver, J, Burn, E, Sawant, R, Marinier, K, Ryan, P, Prieto-Alhambra, D, European Hlth Data Evidence